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AIMS: To measure the glomerular filtration rate (GFR) in adults and children with cystic fibrosis (CF) using a radio-isotope technique as the gold
standard and to compare this to serum creatinine based equations, serum cystatin C levels and tobramycin clearance, and to determine which
method correlates most closely with measured GFR in this population.
Crown Copyright © 2010 Published by Elsevier B.V. on behalf of European Cystic Fibrosis Society. All rights reserved.1. Introduction
We have investigated the utility of cystatin C, a more recent
technique formeasuringGFR. Thismethod had not been validated
in patients with CF at the commencement of this study. Cystatin C
is a cysteine protease inhibitor [1]. It is a non glycosylated low
molecular weight protein that has been shown to be produced
by all nucleated cells. According to the review article by Randers
et al. [2] cystatin C is freely filtered by the renal glomerulus before
beingmetabolized by the proximal tubular epithelial cells i.e. once
cystatin C has been filtered it does not re-enter the circulation in its
original form. Hence because serum cystatin C concentrations are
mainly determined by glomerular filtration, this could be an ideal
endogenous marker for estimating GFR.
Serum cystatin C is assayed from a blood sample using either a
particle enhanced nephelometer (PENIA) or a particle enhanced☆ Initial data for this study was presented at the 31st European Cystic Fibrosis
Conference 11th to 14th June 2008, Prague, Czech Republic.
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doi:10.1016/j.jcf.2009.12.002turbidimeter (PETIA). According to Randers et al. [2] these
assays are “precise, rapid and usable in clinical practice.”
As a simple single blood test this offers significant advantages
over standard invasive methods if it correlates well with GFR.
Currently inAustralia cystatinC is only used for research purposes
and is not reimbursed through Medicare making routine clinical
access to the test an issue.
Currently there are three ways in which renal function is
assessed: Serum creatinine, creatinine clearance (measured or
estimated from serum creatinine using various equations of which
themost commonly used ones in clinical practice are theCockcroft
and Gault equation for adults and the Schwartz equation for
children [3,4]). However for the purposes of this study the
abbreviated Modification of Diet in Renal Disease equation [5]
was also used as well as the updated Schwartz equation [6], or by
using the “gold standard test” to determine GFR. Commonly used
agents for this test include Cr-EDTA, iothalamate, inulin, 99mTc-
DTPA and iohexol. These tests are costly, time consuming, and are
dependent on the accuracy of sample collection [7].
Aminoglycoside antibiotics, usually tobramycin, are widely
used to treat exacerbations of CF lung infections as they are
highly effective against Pseudomonas aeruginosa and syner-
gistic with beta lactam antibiotics [8,9]. Aminoglycosides are.V. on behalf of European Cystic Fibrosis Society. All rights reserved.
Table 1
Patient demographics and clinical characteristics (SD in brackets).
Adults Children
Numbers 20 27
Males/females 14/6 13/14
Age (years) 26.8 (±9.2) 11.4 (±4.7)
Weight (kg) 65 (±12.8) 43.2 (±20.9)
Height (cm) 170 (±9.1) 146 (±27.5)
BMI (kg/m2) 22.4 (±2.6) 18.95 (±2.9)
No. admissions 47 (±23.0) 22 (±21.0)
Table 2
Patient measured clinical characteristics (SD and ranges in brackets).
Adults (n=20) Children (n=27)
Serum creatinine (μmol/L) 68.7 (±7.3, 38–105) 45.9 (±3.8, 26–80)
Serum cystatin C (mg/L) 0.74 (±0.2, 0.53–1.27) 0.70 (±0.1, 0.51–0.92)
Tobramycin clearance
(mL/min/1.73m2)
88.2 (±23.9, 50.9–135) 82.7 (±21.6, 48.8–126.4)
Measured GFR
(mL/min/1.73m2)
113 (±25.3, 68–149) 142 (±27.2, 108–212)
FEV1% predicted 58.4 (±21.2, 20–107) 85.4 (±31.8, 41–126)
Number colonised with
PA at time of study
19 12
Table 3
Results for renal function measurements in mL/min/1.73m2 — mean, SD and
range (in brackets).
Renal function test Mean (adults) Mean (children)
Measured GFR 113 (±25, 68–149) 142 (±27, 108–212)
Estimated GFR
using Cystatin C
119 (±23, 64–158) 122 (±19, 90–175)
Estimated CrCl using
Cockcroft and Gault (adult)
or Schwartz (children)
88 (±29, 52–156) 146 (±27, 88–205)
Tobramycin clearance 88 (±24, 51–135) 77 (±30, 49–126)
Estimated CrCl using
aMDRD (adult) or updated
Schwartz (children)
177 (±78, 83–449) 135 (±25, 82–191)
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they are used. [10] Simple and reliable methods of renal function
assessment are required to support this monitoring.
2. Methodology
2.1. Patient selection
Patients were asked to enter the study during their routine
clinic appointment either at theWomen's and Children's Hospital
(WCH) or the Royal Adelaide Hospital (RAH)
They were eligible for inclusion if they:
• Had a diagnosis of CF confirmed with either a positive sweat
test or identification of 2 CFTR mutations.
• Were over 2 years of age.
• Could provide (either themselves or their parents) informed
consent for participation.
Exclusion criteria
• Having received IV tobramycin within the previous 8 weeks
• Pregnancy or breast-feeding.
• Participated in another study within the last year that exposed
them to radiation.
Patients were able to withdraw from the study at any time.
This study was approved by the research ethics committees
at the RAH, the WCH, and the University of South Australia.
2.2. Measurement of GFR
To ensure that there were no confounding factors there was
at least 8 weeks between the end of a course of tobramycin
therapy and GFR measurements.
GFR was estimated using a 30 MBq dose of 99mTcDTPA.
This method of GFR measurement is convenient, has been
standardized and validated [11]. Approximately 90% of the
99mTcDTPA is eliminated by the kidneys within 24 h and the
absorption radiation dose is 0.042 rad/mCi to the kidney and
0.555 rad/mCi to the bladder [11].
A local anaesthetic cream was applied to the venepuncture
site 1 h prior to commencement of study in those patients who
requested it. Patients had height and weight measured. A
22 gauge or larger cannula was inserted into a vein and the
dose was administered and flushed with a minimum of 10 mL
sodium chloride 0.9% (NS). The exact dose of 99mTcDTPA and
time of administration was recorded as time zero (T0). Further
blood samples were taken at 2, 3, and 4 h post-injection.
2.3. Calculation of GFR
The blood samples were analysed in duplicate. The results
were averaged and normalized to body surface area (BSA) using
the height and weight obtained at the time of the study. Where
the calculated duplicate GFRs varied by N10% the counting and
calculation was repeated with a new set of samples.Using a computer program the plasma count values were
manipulated to allow the plotting of a straight line where the
half life (T½) and Y intercept could be calculated.
GFR =
ðCorrected standard countÞ × ðpatient doseÞ × 0:693
ðCorrected standard doseÞ × ðyinterceptÞ × ðTOÞ × 1000ml=min
The resulting GFR was normalized to a body surface area
(BSA) of 1.73m2 for reporting as mL/min/1.73 m2.
2.4. Measurement of serum cystatin C
On the day of the study, 5 mL of blood was taken for
measurement of cystatin C. The sample was taken before the
administration of the 99mTc-DTPA. After centrifugation the
plasma layer was removed and duplicate 1 mL samples were
pipetted into two test tubes. The samples were frozen at −20 °C
before being sent for analysis. Serum cystatin C levels were
Table 5
ROC Curve results — measured GFRN90mL/min/1.73m2.
Cystatin C Cr equations Tobramycin clearance
Sensitivity 100 100 100
Specificity 85.7 88.1 64.3
Table 4
Results for correlations between measured GFR and estimated renal function
with 95% confidence interval reported in brackets.
Test R value (adults) R value (children)
Cystatin C 0.64
(0.43–0.78)
P=0.0059
0.61
(0.39–0.76)
P=0.0011
Cockcroft and Gault equation
(adults) or Schwartz (children)
0.51
(0.36–0.75)
P=0.0252
0.60
(0.34–0.74)
P=0.0015
Tobramycin clearance 0.1
(−0.83–0.52)
P=0.7117
0.25
(−0.04–0.5)
P=0.1920
aMDRD equation (adults)
or updated Schwartz (children)
0.29
(−0.17–0.65)
P=0.2145
0.60
(0.28–0.80)
P=0.001
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on the BN system analyser. The method was calibrated using a
standard supplied by Dade Behring. The samples were thawed on
the day of analysis, mixed and spun prior to being diluted to 1:100
and then assayed within 4 h. Controls were run at the beginning
and end of the analysis procedure. All control values were within
expected limits which were a SD of ±20% of the assigned value.
The cystatin C values were then used in the MacIsaac equation to
calculate GFR to give a value in mL/min/1.73 m2 [12].
MacIsaacequation :GFR = ð86:7= cystatin C ½mg=LÞ−4:2:
2.5. Measurement of serum creatinine
Bloodwas taken and sent for analysis to the hospital laboratory.
Serum creatinine was measured using a photometric assay on an
Olympus 5400 analyser using the Jaffe alkaline picrate method
(Kinetic colour test).The serum calibrator creatinine value was
traceable to the Isotope Dilution Mass Spectroscopy (IDMS)
method via National Institute Standards and Technology (NIST)
using Standard Reference Material (SRM) 967.Table 6
Bias, precision and accuracy of estimated GFR calculations and tobramycin clearan
Creatinine based equations
Bias Adults: 25.2 (CG) −64.2 (aMDRD)
Children: −3.5 ( Schwartz) 6.6 (Update
Precision Adults: 26.4 (CG) 75 (aMDRD)
Children: 24.3 (Schwartz) 23.4 (Update
Accuracy % (within 30%) Adults: 87 (CG) 65 (aMDRD)
Children: 100 (Schwartz) 81 (Updated S
Accuracy % (within 50%) Adults: 96 (CG) 75 (aMDRD)
Children: 100 (Schwartz) 100 (Updated2.6. Measurement of tobramycin clearance
All patients who had a measured GFR were included in this
analysis provided that they had received intravenous tobramycin
in the 6 months prior to having their GFRmeasured. Tobramycin
monitoring is standardized across both hospitals. Patients receive
tobramycin as an intravenous infusion administered over 30 min.
On day one a blood sample is taken 30 min after the end of the
infusion and the second blood sample is taken between 4 and 6 h
later. The start time of administration and sample times are
recorded. Tobramycin levels are entered into a computerized
kinetics program which calculates the maximum concentration
achieved (Cmax), minimum concentration achieved (Cmin) and
area under the curve (AUC) for that dosing interval. Also
calculated is the half life (t1/2), volume of distribution (Vd) and
clearance (Cl). A decision is made as to whether a dose change is
required. Tobramycin clearance is reported in mL/min so this
was corrected to mL/min/1.73 m2 ensuring all results for renal
function were reported in the same units.
3. Statistical analysis
Since this was a method comparison study a sample size
calculationwas carried out using reference ranges for identifying
patient numbers. One hundred and fifty patients in total were
needed to be recruited to achieve a power of 90% and an α value
of 0.05. This is based on specific reference ranges [13].
All statistical analysis was carried out using the software
program Medcalc® version 10.0.1.
Correlations between the different tests investigated and the
gold standard methodology were calculated using Pearson's
correlation coefficient. Correlations were also calculated for
potential confounders including age, BMI and lung function.
Bland and Altman analysis of the GFR estimates was carried out
and compared with the measured GFR [14]. For the purposes of
this analysis the estimated GFRs include estimated GFR using
Cystatin Cmeasurements, estimated CrCl using creatinine based
equations and tobramycin clearance. The limits of agreement are
identified as fitting within ±1.96 SD of the mean and containing
95% of the values. The mean difference is a measure of accuracy
and the SD is a measure of precision. The sensitivity and
specificity of the tests were also were calculated using the area
under the receiver operating characteristic (ROC) curve
following the methodology by Zweig and Campbell [15]. This
gives a graphical display of the performance of a specific test.ce against the measured values for GFR.
Cystatin C Tobramycin clearance
−4.7 27.1
d Schwartz) 19.6 59.6
20.6 32.0
d Schwartz) 21.7 39.9
85 60
chwartz) 89 8
100 70
Schwartz) 93 40
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means of comparing different tests.
4. Results
4.1. Demographics
Fifty three patients were enrolled and forty seven completed
the study. The mean age was 18 years (range 2 to 54). Twenty
patients were over 18. Demographic and patients clinical charac-
teristics are shown as mean values in Tables 1 and 2. Table 3
shows the mean results for the different methods of measuring
renal function used in the study.
4.2. Correlations
In Table 4 the results are shown for the adult population and
children separately.When using the aMDRD equation rather than
the Cockcroft and Gault equation the correlation was only 0.29 in
comparison to 0.51. However when using the updated Schwartz
formula and comparing it to the original Schwartz formula there
was no significant difference in the two correlations (r=0.60 and
0.60 respectively).
4.3. Sensitivity and specificity
Receiver Operating Characteristic (ROC) curve plots were
plotted to determine the diagnostic accuracy of the investigated
tests for the ability to detect abnormal GFRs when compared to the
gold standardmethod of 99mTcDTPA clearance. Table 5 shows the
results for sensitivity and specificity of the tests for detecting aGFR
of less than 90 mL/min/1.73 m2. This cut off value to distinguish
between abnormal and normal GFRs was chosen due to the small
numbers in this study. Since none of the values for the children
were less than 90 mL/min/1.73 m2 this analysis was conducted on
the whole study sample only. Only four adults and no children had
a measured GFR of b90 mL/min/1.73 m2 in this study.
4.4. Bland and Altman analysis
This analysis was conducted to determine bias, precision and
accuracy of the methods being compared to the gold standard as
seen in Table 6. This has also been represented graphically as
seen in Fig. 1. The limits of agreement would appear to be large
for all three comparisons and are not dissimilar to those found by
Beringer et al. in their study [16]: Using the Cockcroft and Gault
equation for adults the limits of agreement were −27 to +77 but
when using the aMDRD equation the limits of agreement were
significantly larger at −211 to +83.For the Schwartz equation
for children the limits of agreement were −51 to +44 and whenFig. 1. Bland and Altman analysis for differences between estimated GFR and
measured GFR in mL/min/1.73 m2. The x-axis represents the average GFR and
the y-axis represents the difference between the measured GFR and creatinine
based equations (Cockcroft and Gault or aMDRD for adults and Schwartz or
updated Schwartz for children) measuring CrCl or Cystatin C GFR from the
MacIsaac equation or tobramycin clearance. Also plotted are the mean (solid
line) and the 1.96 SD limits (dotted lines).
Fig. 1 (continued ).
Fig. 1 (continued ).
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were similar at −39 to +52. For the tobramycin clearance the
limits of agreement were −36 to +90 for adults and −18 to +138
for children. The limits of agreement for the cystatin C based
GFR were −45 to +36 for adults and −22 to +62 for children.
5. Discussion
Our hypothesis was that cystatin C based equations or tobra-
mycin clearance may be an improvement on current practice. We
129N. Soulsby et al. / Journal of Cystic Fibrosis 9 (2010) 124–129also investigated whether one method was superior to the other
and whether there was a difference between the adult and children
population. Our results showed that there was a small but insig-
nificant difference between using creatinine based equations
and cystatin C based equations in both the adult and children
population when compared with the gold standard and against
each other (p=0.0001 for both). However, using the Cockcroft
and Gault equation in adults appears to be superior to using
the aMDRD equation. With tobramycin clearance there was a
significant difference (p=0.4426) between it and the gold standard
method. These results concur with the study by Smith et al. [17]
where they found the correlation between tobramycin clearance
andmeasuredGFR to be 0.44.The rationale for testing tobramycin
clearance was that universally patients receiving IV tobramycin
will have their levels checked and clearance calculated thus
allowing regular monitoring of renal function. It is disappointing
to note that the correlation between measured GFR and tobra-
mycin clearance was so poor. There seems to be no clear expla-
nation for this. It is known that about 20% of tobramycin is
subjected to tubular reabsorption [18–20] but this does not com-
pletely explain these results. The explanation may be associated
with the measurement of the kinetic parameters for tobramycin.
There has been some discussion as to the appropriate sampling
times for tobramycin TDM [21]. According to Aminimanizani et
al. sampling as we do, 30 min after the end of the 30 min infusion
may give a concentration that is still in the distribution phase [21].
Their recommendation when using a one compartment model for
TDM, which is the model used in this study, is to wait and sample
2 h after the end of the infusion ensuring that the distribution phase
is complete. Perhaps repeating this study and waiting longer may
allow for an improved correlation to be seen.
Unlike the results of Beringer's study, in our population
cystatin Cwas not statistically significantly better than any of the
other methods for estimating renal function. Again the issue may
be small numbers as this was true whether we assessed all the
patients in the study (n=47) or split them into adults and
children. We did not see a statistically significant difference
between adults and children with regard to the methods used for
testing. However, if we want a true measure of renal function in
someone with CF these methods cannot replace the invasive
gold standard test.
A larger prospective study (as per the initial power calculation)
is necessary to conclusively validate the role of cystatin C in
patients with CF but until this is available monitoring renal
function, at least annually and during each treatment with IV
aminoglycosides (or IV colistin) may be the most reliable way of
recognising early changes in renal function allowing time for
intervention to prevent further damage. It is important that this
information is looked at prospectively regardless of the
methodology employed. This is particularly important in the CF
population due to their increased life expectancy and likely
exposure to more nephrotoxic treatments. Preservation of renal
function needs to be a priority for all these patients. Raising
awareness of this issue and choosing a consistent method formeasuring renal function is important because the superiority of
one methodology over another remains unproven.
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